Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pharmacogenetics: the slow, the rapid, and the ultrarapid.

Literature DB >> 8134334

Pharmacogenetics: the slow, the rapid, and the ultrarapid.

U A Meyer¹.

Abstract

Mesh：

Substances：
Debrisoquin

Year: 1994 PMID： 8134334 PMCID： PMC43291 DOI： 10.1073/pnas.91.6.1983

Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN： 0027-8424 Impact factor: 11.205

× No keyword cloud information.

26 in total

1. Drug reactions enzymes, and biochemical genetics.

Authors: A G MOTULSKY
Journal: J Am Med Assoc Date: 1957-10-19

Review 2. N-acetyltransferase.

Authors: D A Evans
Journal: Pharmacol Ther Date: 1989 Impact factor: 12.310

3. DNA amplification is rare in normal human cells.

Authors: J A Wright; H S Smith; F M Watt; M C Hancock; D L Hudson; G R Stark
Journal: Proc Natl Acad Sci U S A Date: 1990-03 Impact factor: 11.205

4. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification.

Authors: M Heim; U A Meyer
Journal: Lancet Date: 1990-09-01 Impact factor: 79.321

5. De novo amplification within a "silent" human cholinesterase gene in a family subjected to prolonged exposure to organophosphorous insecticides.

Authors: C A Prody; P Dreyfus; R Zamir; H Zakut; H Soreq
Journal: Proc Natl Acad Sci U S A Date: 1989-01 Impact factor: 11.205

Review 6. Regulation and mechanisms of mammalian gene amplification.

Authors: G R Stark
Journal: Adv Cancer Res Date: 1993 Impact factor: 6.242

7. Molecular mechanism of slow acetylation of drugs and carcinogens in humans.

Authors: M Blum; A Demierre; D M Grant; M Heim; U A Meyer
Journal: Proc Natl Acad Sci U S A Date: 1991-06-15 Impact factor: 11.205

8. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.

Authors: F Broly; U A Meyer
Journal: Pharmacogenetics Date: 1993-06

9. Localization of the CYP2D gene locus to human chromosome 22q13.1 by polymerase chain reaction, in situ hybridization, and linkage analysis.

Authors: A C Gough; C A Smith; S M Howell; C R Wolf; S P Bryant; N K Spurr
Journal: Genomics Date: 1993-02 Impact factor: 5.736

10. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism.

Authors: F J Gonzalez; R C Skoda; S Kimura; M Umeno; U M Zanger; D W Nebert; H V Gelboin; J P Hardwick; U A Meyer
Journal: Nature Date: 1988-02-04 Impact factor: 49.962

12 in total

Review 1. [Pharmacogenomics. What is relevant for the internal medicine specialist?].

Authors: P Krüth; M Wehling
Journal: Internist (Berl) Date: 2003-12 Impact factor: 0.743

2. Inference from the relationships between linkage disequilibrium and allele frequency distributions of 240 candidate SNPs in 109 drug-related genes in four Asian populations.

Authors: Pei-Chieng Cha; Ryo Yamada; Akihiro Sekine; Yusuke Nakamura; Chong-Lek Koh
Journal: J Hum Genet Date: 2004-09-11 Impact factor: 3.172

Pharmacogenetics: the slow, the rapid, and the ultrarapid.

1. Drug reactions enzymes, and biochemical genetics.

Review 2. N-acetyltransferase.

3. DNA amplification is rare in normal human cells.

4. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification.

5. De novo amplification within a "silent" human cholinesterase gene in a family subjected to prolonged exposure to organophosphorous insecticides.

Review 6. Regulation and mechanisms of mammalian gene amplification.

7. Molecular mechanism of slow acetylation of drugs and carcinogens in humans.

8. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.

9. Localization of the CYP2D gene locus to human chromosome 22q13.1 by polymerase chain reaction, in situ hybridization, and linkage analysis.

10. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism.

Review 1. [Pharmacogenomics. What is relevant for the internal medicine specialist?].

2. Inference from the relationships between linkage disequilibrium and allele frequency distributions of 240 candidate SNPs in 109 drug-related genes in four Asian populations.

3. CYP2D6 genotype and phenotype determination in a Mexican Mestizo population.

4. Genetic polymorphism of CYP2C19 in Maharashtrian population.

Review 5. Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist?

Review 6. Overview of enzymes of drug metabolism.

Review 7. Pharmacogenetics and the treatment of functional gastrointestinal disorders.

Review 8. Addressing phenoconversion: the Achilles' heel of personalized medicine.

9. Genetic Polymorphism of Cytochrome p450 (2C19) Enzyme in Iranian Turkman Ethnic Group.

10. Association between the CYP1A1 gene polymorphism and susceptibility to emphysema and lung cancer.